Monte Rosa (GLUE) | Financial Analysis & Statements
Monte Rosa Therapeutics Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
2.8M
Operating Income
-49.7M
-1,787.67%
Net Income
-46.1M
-1,658.94%
EPS (Diluted)
$-0.70
Balance Sheet Metrics
Total Assets
448.7M
Total Liabilities
215.6M
Shareholders Equity
233.1M
Debt to Equity
0.93
Cash Flow Metrics
Operating Cash Flow
-53.2M
Free Cash Flow
-43.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Monte Rosa Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 123.7M | 75.6M | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 141.5M | 121.6M | 111.3M | 85.1M | 57.2M |
| Selling, General & Administrative | 36.4M | 35.2M | 32.0M | 27.3M | 15.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 177.9M | 156.7M | 143.3M | 112.4M | 72.9M |
| Operating Income | -54.2M | -81.1M | -143.3M | -112.4M | -72.9M |
| Operating Margin % | -43.8% | -107.3% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 12.9M | 10.6M | 9.3M | 3.8M | 46.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 1.5M | 416.0K | -1.0M | 119.0K | -1.1M |
| Pre-tax Income | -39.7M | -70.1M | -135.0M | -108.5M | -74.0M |
| Income Tax | -1.1M | 2.6M | 338.0K | 0 | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -38.6M | -72.7M | -135.4M | -108.5M | -74.0M |
| Net Margin % | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -47.4M | -73.4M | -136.1M | -108.8M | -70.6M |
| EPS (Basic) | - | $-1.18 | $-2.63 | $-2.30 | $-2.96 |
| EPS (Diluted) | - | $-1.18 | $-2.63 | $-2.30 | $-2.96 |
| Basic Shares Outstanding | - | 61507446 | 51396961 | 47227370 | 25000124 |
| Diluted Shares Outstanding | - | 61507446 | 51396961 | 47227370 | 25000124 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Monte Rosa Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 129.9M | 224.3M | 128.1M | 54.9M | 346.1M |
| Short-term Investments | 247.2M | 147.9M | 104.3M | 207.9M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 4.5M | 5.1M | 3.3M | 4.4M | 2.6M |
| Total Current Assets | 393.2M | 377.4M | 236.2M | 275.9M | 348.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 51.4M | 51.9M | 50.9M | 52.6M | 12.3M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 5.1M | 5.0M | 4.9M | 4.6M | 5.3M |
| Total Non-Current Assets | 55.5M | 61.3M | 67.5M | 66.5M | 17.7M |
| Total Assets | 448.7M | 438.7M | 303.8M | 342.4M | 366.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.6M | 17.2M | 11.2M | 7.9M | 6.6M |
| Short-term Debt | 4.4M | 3.7M | 3.2M | 3.1M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.6M | 3.4M | 1.7M | 5.0M | 840.0K |
| Total Current Liabilities | 64.2M | 156.9M | 46.6M | 25.6M | 16.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 34.8M | 39.0M | 42.9M | 43.9M | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 151.4M | 58.8M | 77.9M | 45.4M | 2.2M |
| Total Liabilities | 215.6M | 215.8M | 124.5M | 71.0M | 18.8M |
| Equity | |||||
| Common Stock | 7.0K | 6.0K | 5.0K | 5.0K | 5.0K |
| Retained Earnings | -477.2M | -438.6M | -365.9M | -230.5M | -122.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 233.1M | 222.9M | 179.2M | 271.4M | 347.5M |
| Key Metrics | |||||
| Total Debt | 39.2M | 42.7M | 46.0M | 47.0M | 0 |
| Working Capital | 329.0M | 220.5M | 189.6M | 250.3M | 332.0M |
Balance Sheet Composition
Monte Rosa Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -38.6M | -72.7M | -135.4M | -108.5M | -74.0M |
| Depreciation & Amortization | 8.4M | 8.1M | 6.2M | 3.7M | 2.1M |
| Stock-Based Compensation | 18.9M | 18.1M | 16.7M | 11.7M | 5.2M |
| Working Capital Changes | -17.6M | 88.8M | 67.8M | -1.0M | 403.0K |
| Operating Cash Flow | -29.0M | 42.3M | -44.6M | -89.3M | -65.3M |
| Investing Activities | |||||
| Capital Expenditures | -4.7M | -4.0M | -19.0M | -12.8M | -9.7M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -376.7M | -230.4M | -103.2M | -384.4M | 0 |
| Investment Sales | 279.5M | 189.9M | 210.9M | 178.0M | 0 |
| Investing Cash Flow | -101.8M | -44.5M | 88.8M | -219.2M | -9.7M |
| Financing Activities | |||||
| Share Repurchases | -357.0K | -641.0K | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 23.9M | 47.3M | -116.0K | 19.7M | 377.4M |
| Free Cash Flow | -27.5M | 38.0M | -62.8M | -105.4M | -69.1M |
| Net Change in Cash | -107.0M | 45.2M | 44.1M | -288.8M | 302.5M |
Cash Flow Trend
Monte Rosa Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
49.22
Forward P/E
-11.86
Price to Book
5.67
Price to Sales
13.05
PEG Ratio
-0.12
Profitability Ratios
Profit Margin
-31.23%
Operating Margin
-1,787.67%
Return on Equity
-16.94%
Return on Assets
-7.64%
Financial Health
Current Ratio
6.12
Debt to Equity
16.82
Beta
1.64
Per Share Data
EPS (TTM)
$-0.46
Book Value per Share
$3.56
Revenue per Share
$1.49
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GLUE | 1.6B | 49.22 | 5.67 | -16.94% | -31.23% | 16.82 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






